Compare Dropbox Inc (DBX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Pfizer Inc — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.19B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 22.2× Dropbox Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Dropbox Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Pfizer Inc for 158 Days on average.
| DBX | PFE | |
|---|---|---|
Market Cap | $7.19B | $159.59B |
Volume | 2,804,312 | 30,937,010 |
Sector | Technology | Health |
52-Week High | $37.74 | $29.02 |
52-Week Low | $22.06 | $23.67 |
Typical Hold Time | 97 Days | 158 Days |
Enterprise Value | $10.05B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $34.14, up 1.22% on the day, with a bearish technical signal and mixed analyst ratings. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $0.728. Revenue remains stable around $2.5B annually, with a high gross margin of 79.72%, but net cash flow turned negative in 2025 due to significant financing outflows. Recent news highlights insider selling and a security breach affecting 5,000 accounts.
The outlook is cautious; while profitability is solid, stagnant revenue growth and high debt levels pose risks. The consensus price target of $26.83 suggests downside potential. Investor sentiment is divided, with technical indicators signaling bearish pressure. Key risks include competitive threats and execution challenges in a mature market.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
